Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.46 |
| ▸ | CCR8 | P51685 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 8/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | ALPL | P05186 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | ALPI | P09923 | 1/20 | 0.37 |
| ▸ | ALPG | P10696 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14085152 | 0.89 | CCR1 (0.67) | CCR1CCR8KCNH2CXCR4TGFBR1 | |
| SCHEMBL12450064 | 0.87 | PARP1 (0.44) | CCR1CCR8KCNH2CXCR4PARP1 | |
| SCHEMBL13623090 | 0.87 | ASIC3 (0.48) | CCR1CCR8CXCR4TGFBR1NOS1 | |
| SCHEMBL45869 | 0.86 | KCNH2 (0.52) | KCNH2CXCR4PARP1HRH4GRIN2D | |
| SCHEMBL13596181 | 0.85 | KDM4E (0.63) | CCR1CCR8TGFBR1KDM4ELMNA | |
| SCHEMBL13283433 | 0.84 | RAB9A (0.60) | TP53HSP90AA1ALOX15SMN1; SMN2TDP1 | |
| SCHEMBL23457336 | 0.84 | IDH1 (0.35) | CCR1CCR8KCNH2CXCR4PARP1 | |
| SCHEMBL24581100 | 0.84 | KDM4E (0.67) | CCR1CCR8TGFBR1KDM4ELMNA | |
| SCHEMBL13826881 | 0.84 | CHRNA7 (0.35) | CCR1CCR8KCNH2CXCR4PARP1 | |
| SCHEMBL11564452 | 0.83 | KCNH2 (0.50) | KCNH2CXCR4PARP1HRH4GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022132048-A1 | PHOSPHORUS COMPOUNDS AND METHODS THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2022-06-23 | — | — | WO | disclosed |
| US-11014886-B2 | Method for preparing 2,2′-dipyridine and derivatives thereof | NANJING REDSUN BIOCHEMISTRY CO., LTD. (CN) | 2021-05-25 | — | — | US | disclosed |
| US-20200331857-A1 | METHOD FOR PREPARING 2,2'-DIPYRIDINE AND DERIVATIVES THEREOF | NANJING REDSUN BIOCHEMISTRY CO., LTD. (CN) | 2020-10-22 | — | — | US | disclosed |
| US-20150297576-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | TRASLATIONAL CANCER DRUGS PHARMA S L (ES) | 2015-10-22 | — | — | US | disclosed |
| US-20150297576-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | TRASLATIONAL CANCER DRUGS PHARMA S L (ES) | 2015-10-22 | — | — | US | disclosed |
| US-20150098927-A1 | METHODS FOR TREATMENT AND DIAGNOSIS OF CANCER | TRASLATIONAL CANCER DRUGS PHARMA, S.L. (ES) | 2015-04-09 | — | — | US | disclosed |
| US-20150098927-A1 | METHODS FOR TREATMENT AND DIAGNOSIS OF CANCER | TRASLATIONAL CANCER DRUGS PHARMA, S.L. (ES) | 2015-04-09 | — | — | US | disclosed |
| US-20150004252-A1 | METHOD FOR PREDICTING THE CLINICAL RESPONSE TO CHEMOTHERAPY IN A SUBJECT WITH CANCER | TRASLATIONAL CANCER DRUGS PHARMA, S.L (ES) | 2015-01-01 | — | — | US | disclosed |
| US-20150004252-A1 | METHOD FOR PREDICTING THE CLINICAL RESPONSE TO CHEMOTHERAPY IN A SUBJECT WITH CANCER | TRASLATIONAL CANCER DRUGS PHARMA, S.L (ES) | 2015-01-01 | — | — | US | disclosed |
| EP-2340042-B1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | TRASLATIONAL CANCER DRUGS PHARMA S L (ES) | 2014-07-23 | — | — | EP | disclosed |
| EP-2316970-A2 | METHODS FOR THE TREATMENT AND DIAGNOSIS OF CANCER | Traslational Cancer Drugs Pharma, S.L. (ES) | 2011-05-04 | — | — | EP | disclosed |
| US-20110046336-A1 | TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | SUMITOMO CHEMICAL COMPANY, LIMITED | 2011-02-24 | — | — | US | disclosed |
| US-7781458-B2 | Derivatives of pyridine and quinoline | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2010-08-24 | — | — | US | disclosed |
| US-7781458-B2 | Derivatives of pyridine and quinoline | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2010-08-24 | — | — | US | disclosed |
| EP-2192124-A1 | TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND WITH THE TRANSITION METAL COMPLEX | Sumitomo Chemical Company, Limited (JP) | 2010-06-02 | — | — | EP | disclosed |
| US-20100068302-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | TRASLATIONAL CANCER DRUGS PHARMA, S.L. (ES) | 2010-03-18 | — | — | US | disclosed |
| US-20100068302-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | TRASLATIONAL CANCER DRUGS PHARMA, S.L. (ES) | 2010-03-18 | — | — | US | disclosed |
| EP-2085386-A2 | Pyridinium and quinolinium derivatives as Choline kinase inhibitors | Consejo Superior De Investigaciones Científicas (ES) | 2009-08-05 | — | — | EP | disclosed |
| US-20070185170-A1 | Derivatives of pyridine and quinoline | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2007-08-09 | — | — | US | disclosed |
| US-20070185170-A1 | Derivatives of pyridine and quinoline | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150297576-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | ASAH1, ACER2, ASAH2 | CCR1 573/4885CCR8 1170/4885KCNH2 2282/4885 |
| US-20110046336-A1 | TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | C9, C5, AP1M1 | CCR1 510/4885CCR8 2317/4885KCNH2 150/4885 |
| US-20200331857-A1 | METHOD FOR PREPARING 2,2'-DIPYRIDINE AND DERIVATIVES THEREOF | HRH2, AMPD2, QDPR | CCR1 2897/4885CCR8 4285/4885KCNH2 456/4885 |
| US-20070185170-A1 | Derivatives of pyridine and quinoline | CHKA, CHKB, PHOSPHO1 | CCR1 1569/4885CCR8 4258/4885KCNH2 704/4885 |
| US-20150098927-A1 | METHODS FOR TREATMENT AND DIAGNOSIS OF CANCER | CHKA, CHKB, CEPT1 | CCR1 2006/4885CCR8 3536/4885KCNH2 2575/4885 |
| US-20100068302-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | ASAH1, ACER2, ASAH2 | CCR1 573/4885CCR8 1170/4885KCNH2 2282/4885 |
| US-20150004252-A1 | METHOD FOR PREDICTING THE CLINICAL RESPONSE TO CHEMOTHERAPY IN A SUBJECT WITH CANCER | CHKA, CHKB, DCK | CCR1 447/4885CCR8 1152/4885KCNH2 1646/4885 |
| US-11014886-B2 | Method for preparing 2,2′-dipyridine and derivatives thereof | HRH2, AMPD2, DPYD | CCR1 2915/4885CCR8 4291/4885KCNH2 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.